Alzheimers Research & Therapy

Papers
(The H4-Index of Alzheimers Research & Therapy is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody350
Immediate and long-term consequences of COVID-19 infections for the development of neurological disease324
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval204
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease171
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering141
Cognitive impact of COVID-19: looking beyond the short term139
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification132
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology117
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment109
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease106
Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment95
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia93
Imaging biomarkers in neurodegeneration: current and future practices86
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review84
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau23182
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease79
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review73
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes72
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease70
Reproducibility of EEG functional connectivity in Alzheimer’s disease68
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study68
Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance65
The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease62
The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study59
Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease58
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease58
White matter hyperintensities across the adult lifespan: relation to age, Aβ load, and cognition57
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study57
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis55
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two54
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals54
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice54
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial53
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice52
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia52
Effects of low- and high-intensity physical exercise on physical and cognitive function in older persons with dementia: a randomized controlled trial51
The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease51
Portals to frailty? Data-driven analyses detect early frailty profiles50
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach49
The Alzheimer’s disease drug development landscape48
Identification of potential blood biomarkers for early diagnosis of Alzheimer’s disease through RNA sequencing analysis47
An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease47
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression47
One third of dementia cases can be prevented within the next 25 years by tackling risk factors. The case “for” and “against”47
A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse47
Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment47
Retinal microvasculature dysfunction is associated with Alzheimer’s disease and mild cognitive impairment46
0.046655178070068